The price of a popular genetic test that predicts womens risk of breast cancer is likely to drop in the New Year after the agency that administers Medicare benefits said it would slash its reimbursement rate for the test by half The rate cut goes into effect on Jan   with consequences for genetictesting companies particularly Myriad Genetics Inc the dominant supplier of screenings for mutations in the genes known as BRCA and BRCA Medicare will pay a maximum of  for the BRCA test a  decline from
  